BidaskClub upgraded shares of ATRION (NASDAQ:ATRI) from a strong sell rating to a sell rating in a research note released on Saturday.
NASDAQ:ATRI opened at $634.50 on Friday. The company has a market cap of $1,177.40, a price-to-earnings ratio of 34.39 and a beta of 0.67. ATRION has a fifty-two week low of $504.26 and a fifty-two week high of $694.00.
ATRION (NASDAQ:ATRI) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. The company had revenue of $34.02 million for the quarter. ATRION had a net margin of 24.96% and a return on equity of 19.53%.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 30th. Stockholders of record on Thursday, March 15th were paid a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend was Wednesday, March 14th.
Several hedge funds have recently modified their holdings of the company. MetLife Investment Advisors LLC purchased a new position in shares of ATRION in the 4th quarter valued at $390,000. Millennium Management LLC raised its stake in shares of ATRION by 96.0% in the 4th quarter. Millennium Management LLC now owns 784 shares of the medical instruments supplier’s stock valued at $494,000 after acquiring an additional 384 shares during the period. Stone Ridge Asset Management LLC purchased a new position in shares of ATRION in the 4th quarter valued at $271,000. Deutsche Bank AG raised its stake in shares of ATRION by 19.9% in the 4th quarter. Deutsche Bank AG now owns 8,008 shares of the medical instruments supplier’s stock valued at $5,047,000 after acquiring an additional 1,328 shares during the period. Finally, Advisor Group Inc. raised its stake in shares of ATRION by 11.6% in the 4th quarter. Advisor Group Inc. now owns 992 shares of the medical instruments supplier’s stock valued at $625,000 after acquiring an additional 103 shares during the period. 59.04% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “ATRION (ATRI) Lifted to “Sell” at BidaskClub” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/24/atrion-atri-lifted-to-sell-at-bidaskclub.html.
ATRION Company Profile
Atrion Corp. engages in the manufacture and development of products for medical applications. It involves in the marketing of components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It specializes in the fluid delivery, as well as ophthalmic and cardiovascular devices.
Receive News & Ratings for ATRION Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRION and related companies with MarketBeat.com's FREE daily email newsletter.